| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.6 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |